|
1
|
Doganis D, Panagopoulou P, Tragiannidis A,
Vichos T, Moschovi M, Polychronopoulou S, Rigatou E,
Papakonstantinou E, Stiakaki E, Dana H, et al: Survival and
mortality rates of Wilms tumour in Southern and Eastern European
countries: Socioeconomic differentials compared with the United
States of America. Eur J Cancer. 101:38–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan X, Wang J, Tang J, Tian X, Jin L, Li
M, Zhang Z and He D: A nomogram for predicting Cancer-specific
survival in children with wilms tumor: A study based on SEER
database and external validation in China. Front Public Health.
10:8298402022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vujanić GM, Gessler M, Ooms AHAG, Collini
P, Coulomb-l'Hermine A, D'Hooghe E, de Krijger RR, Perotti D,
Pritchard-Jones K, Vokuhl C, et al: The UMBRELLA SIOP-RTSG 2016
Wilms tumour pathology and molecular biology protocol. Nat Rev
Urol. 15:693–701. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spreafico F, Fernandez CV, Brok J, Nakata
K, Vujanic G, Geller JI, Gessler M, Maschietto M, Behjati S,
Polanco A, et al: Wilms tumour. Nat Rev Dis Primers. 1:752021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jain J, Sutton KS and Hong AL: Progress
update in pediatric renal tumors. Curr Oncol Rep. 23:332021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bahoush G and Saeedi E: Outcome of
Children with Wilms'tumor indeveloping countries. Med Life.
13:484–489. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan CC, To KF, Yuen HL, Shing Chiang AK,
Ling SC, Li CH, Cheuk DK, Li CK and Shing MM: A 20-year prospective
study of Wilms tumor and other kidney tumors: A report from Hong
Kong pediatric hematology and oncology study group. J Pediatr
Hematol Oncol. 36:445–450. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Millar AJW, Cox S and Davidson A:
Management of bilateral Wilms tumours. Pediatr Surg Int.
33:737–745. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dome JS, Graf N, Geller JI, Fernandez CV,
Mullen EA, Spreafico F, Van den Heuvel-Eibrink M and
Pritchard-Jones K: Advances in wilmstumor treatment and biology:
Progress Through In-ternational Collaboration. J Clin Oncol.
27:2999–3007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park JE, Noh OK, Lee Y, Choi HS, Han JW,
Hahn SM, Lyu CJ, Lee JW, Yoo KH, Koo HH, et al: Loss of
Heterozygosity at chromosome 16q is a negative prognostic factor in
Korean pediatric patients with favorable histology Wilms tumor: A
report of the Korean pediatric hematology oncology group (K-PHOG).
Cancer Res Treat. 52:438–445. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dix DB, Fernandez CV, Chi YY, Mullen EA,
Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel
NL, et al: AREN0532 and AREN0533 study committees. Augmentation of
therapy for combined loss of heterozygosity 1p and 16q in favorable
histology wilms tumor: A Children's oncology group AREN0532 and
AREN0533 study report. J Clin Oncol. 30:2769–2777. 2019. View Article : Google Scholar
|
|
12
|
Li K, Zhang K, Yuan H and Fan C:
Prognostic role of primary tumor size in Wilms tumor. Oncol Lett.
27:1642024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fernandez CV, Mullen EA, Chi YY, Ehrlich
PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE,
Gow KW, et al: Outcome and prognostic factors in stage III
Favorable-histology wilms tumor: A report from the Children's
oncology group study AREN0532. J Clin Oncol. 36:254–261. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dome JS, Mullen EA, Dix DB, Gratias EJ,
Ehrlich PF, Daw NC, Geller JI, Chintagumpala M, Khanna G,
Kalapurakal JA, et al: Impact of the first generation of Children's
oncology group clinical trials on clinical practice for wilms
tumor. J Natl Compr Canc Netw. 19:978–985. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nelson MV, van den Heuvel-Eibrink MM, Graf
N and Dome JS: New approaches to risk stratification for Wilms
tumor. Curr Opin Pediatr. 33:40–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haruta M, Arai Y, Okita H, Tanaka Y,
Takimoto T, Sugino RP, Yamada Y, Kamijo T, Oue T, Fukuzawa M, et
al: Combined genetic and chromosomal characterization of wilms
tumors identifies chromosome 12 Gain as a potential new marker
predicting a favorable outcome. Neoplasia. 21:117–131. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yao W, Weng S, Li K, Shen J, Dong R and
Dong K: Bilateral Wilms tumor: 10-year experience from a single
center in China. Transl Cancer Res. 13:879–887. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian XM, Ma W, Shi QL, Lu P, Liu X, Lin T,
He D and Wei G: Clinical analysis of 43 cases of Wilms tumor
treated with the CCCG-WT-2016 regimen. J Clin Pediatrics.
12:915–920. 2020.
|
|
19
|
Urology Group, Pediatric Surgery Society,
Chinese Medical Association, . Pediatric nephroblastoma diagnosis
and treatment expert consensus. Chin J Pediatr Surge. 7:585–590.
2020.
|
|
20
|
de Faria LL, Ponich Clementino C, Véras
FASE, Khalil DDC, Otto DY, Oranges Filho M, Suzuki L and Bedoya MA:
Staging and restaging pediatric abdominal and pelvic tumors: A
practical guide. Radiographics. 44:e2301752024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geller JI, Hong AL, Vallance KL, Evageliou
N, Aldrink JH, Cost NG, Treece AL, Renfro LA and Mullen EA; COG
Renal Tumor Committee, : Children's oncology Group's 2023 blueprint
for research: Renal tumors. Pediatr Blood Cancer. 70 (Suppl
6):e305862023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dome JS, Graf N, Geller JI, Fernandez CV,
Mullen EA, Spreafico F, Van den Heuvel-Eibrink M and
Pritchard-Jones K: Advances in wilms tumor treatment and biology:
Progress through international collaboration. J Clin Oncol.
33:2999–3007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong KF, Reulen RC, Winter DL, Guha J,
Fidler MM, Kelly J, Lancashire ER, Pritchard-Jones K, Jenkinson HC,
Sugden E, et al: Risk of adverse healthand social outcomes up to 50
years after Wilms tumor: The British childhood cancer survivor
study. J Clin Oncol. 34:1772–1779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brok J, Mavinkurve-Groothuis AMC, Drost J,
Perotti D, Geller JI, Walz AL, Geoerger B, Pasqualini C, Verschuur
A, Polanco A, et al: Unmet needs for relapsed or refractory Wilms
tumour: Mapping the molecular features, exploring organoids and
designing early phase trials-A collaborative SIOP-RTSG, COG and
ITCC session at the first SIOPE meeting. Eur J Cancer. 144:113–122.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo X, Deng C, Liu F, Liu X, Lin T, He D
and Wei G: HnRNPL promotes Wilms tumor progression by regulating
the p53 and Bcl2 pathways. Onco Targets Ther. 12:4269–4279. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Phelps HM, Al-Jadiry MF, Corbitt NM,
Pierce JM, Li B, Wei Q, Flores RR, Correa H, Uccini S, Frangoul H,
et al: Molecular and epidemiologic characterization of Wilms tumor
from Baghdad, Iraq. World J Pediatr. 14:585–593. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Lou S, Huang X, Mo Y, Wang Z, Zhu
J, Tian X, Shi J, Zhou H, He J and Ruan J: The association of
miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in
Chinese children. Biosci Rep. 40:BSR201942022020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koshinaga T, Takimoto T, Oue T, Okita H,
Tanaka Y, Nozaki M, Tsuchiya K, Inoue E, Haruta M, Kaneko Y and
Fukuzawa M: Outcome of renal tumors registered in Japan Wilms Tumor
Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group
(JCCG). Pediatr Blood Cancer. 65:e270562018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hol JA, Lopez-Yurda MI, Van Tinteren H,
Van Grotel M, Godzinski J, Vujanic G, Oldenburger F, De Camargo B,
Ramírez-Villar GL, Bergeron C, et al: Prognostic significance of
age in 5631 patients with Wilms tumour prospectively registered in
International Society of Paediatric Oncology (SIOP) 93-01 and 2001.
PLoS One. 14:e02213732019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chagtai T, Zill C, Dainese L, Wegert J,
Savola S, Popov S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, et al:
Gain of 1q as a prognostic biomarker in wilms tumors (WTs) treated
with preoperative chemotherapy in the international society of
paediatric oncology (SIOP) WT 2001 Trial: A SIOP renal tumours
biology consortium study. J Clin Oncol. 34:3195–3203. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ehrlich PF, Anderson JR, Ritchey ML, Dome
JS, Green DM, Grundy PE, Perlman EJ, Kalapurakal JA, Breslow NE and
Shamberger RC: Clinicopathologic findings predictive of relapse in
children with stage III favorable-histology Wilms tumor. J Clin
Oncol. 31:1196–1201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oue T, Koshinaga T, Takimoto T, Okita H,
Tanaka Y, Nozaki M, Haruta M, Kaneko Y and Fukuzawa M; Renal Tumor
Committee of the Japanese Children's Cancer Group, : Renal tumor
committee of the Japanese Children's cancer group. Anaplastic
histology Wilms' tumors registered to the Japan Wilms' Tumor study
group are less aggressive than that in the National Wilms' tumor
study 5. Pediatr Surg Int. 32:851–855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Groenendijk A, Spreafico F, de Krijger RR,
Drost J, Brok J, Perotti D, van Tinteren H, Venkatramani R,
Godziński J, Rübe C, et al: Prognostic factors for wilms tumor
recurrence: A review of the literature. Cancers (Basel).
13:31422021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Islam S, Moinuddin Mir AR, Raghav A, Habib
S, Alam K and Ali A: Glycation, oxidation and glycoxidation of IgG:
A biophysical, biochemical, immunological and hematological study.
J Biomol Struct Dyn. 36:2637–2653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gadd S, Huff V, Walz AL, Ooms AHAG,
Armstrong AE, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D,
Chen QR, et al: A Children's oncology group and TARGET initiative
exploring the genetic landscape of Wilms tumor. Nat Genet.
49:1487–1494. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hol JA, Lopez-Yurda MI, Van Tinteren H,
Van Grotel M, Godzinski J, Vujanic G, Oldenburger F, De Camargo B,
Ramírez-Villar GL, Bergeron C, et al: Prognostic significance of
age in 5631 patients with Wilms tumour prospectively registered in
SIOP 93-01 and 2001. PLoS One. 14:e02213732019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dome JS, Perlman EJ and Graf N: Risk
stratification for wilms tumor: Current approach and future
directions. Am Soc Clin Oncol Educ Book. 215–223. 2014.doi:
10.14694/EdBook_AM.2014.34.215. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perotti D, Williams RD, Wegert J,
Brzezinski J, Maschietto M, Ciceri S, Gisselsson D, Gadd S, Walz
AL, Furtwaengler R, et al: Hallmark discoveries in the biology of
Wilms tumour. Nat Rev Urol. 21:158–180. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Madanat-Harjuoja LM, Renfro LA, Klega K,
Tornwall B, Thorner AR, Nag A, Dix D, Dome JS, Diller LR, Fernandez
CV, et al: Circulating tumor DNA as a biomarker in patients with
stage iii and iv Wilms tumor: Analysis from a Children's oncology
group trial, AREN0533. J Clin Oncol. 40:3047–3056. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gratias EJ, Dome JS, Jennings LJ, Chi YY,
Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV
and Perlman EJ: Association of chromosome 1q gain with inferior
survival in Favorable-histology wilms tumor: A report from the
Children's oncology group. J Clin Oncol. 34:3189–3194. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Q, Chen J, Wang C, Chen X, Liu J,
Zhou L and Liu Y: MicroRNA-466o-3p mediates β-catenin-induced
podocyte injury by targeting Wilms tumor 1. FASEB J.
34:14424–14439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mohamed FS, Jalal D, Fadel YM, El-Mashtoly
SF, Khaled WZ, Sayed AA and Ghazy MA: Characterization and
comparative profiling of piRNAs in serum biopsies of pediatric
Wilms tumor patients. Cancer Cell Int. 25:1632025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ortiz MV, Ahmed S, Burns M, Henssen AG,
Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan
J, et al: Prohibitin is a prognostic marker and therapeutic target
to block chemotherapy resistance in Wilms' tumor. JCI Insight.
4:e1270982019. View Article : Google Scholar : PubMed/NCBI
|
